{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=4", "query": { "intervention": "Arm 1- Dose Escalation", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 959, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T09:19:05.219Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01300611", "title": "TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Double Cord Blood Transplant", "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Myelofibrosis", "Acute Lymphoblastic Leukemia", "Chronic Myelocytic Leukemia", "Non Hodgkins Lymphoma", "Hodgkins Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "TXA127 300 mcg/kg/day", "type": "DRUG" }, { "name": "TXA127 1000 mcg/kg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tarix Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 20, "start_date": "2011-01", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01300611" }, { "nct_id": "NCT06736704", "title": "SNV4818 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "SNV4818", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pikavation Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2025-02-20", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 5, "location_summary": "Los Angeles, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06736704" }, { "nct_id": "NCT06377852", "title": "The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Palbociclib 125mg", "type": "DRUG" }, { "name": "Ribociclib 600mg", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Society of Clinical Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 500, "start_date": "2024-10-29", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 92, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 79 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06377852" }, { "nct_id": "NCT04957290", "title": "A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors" ], "interventions": [ { "name": "NOX66", "type": "DRUG" }, { "name": "EBRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Noxopharm Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-10-25", "completion_date": "2023-06-07", "has_results": true, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 2, "location_summary": "Beverly Hills, California • Houston, Texas", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04957290" }, { "nct_id": "NCT05581004", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors", "NSCLC", "HNSCC", "Melanoma", "TNBC", "Esophageal Cancer", "Gastric Cancer", "Cervical Cancer", "Colorectal Cancer", "Urothelial Carcinoma", "Clear Cell RCC", "HCC" ], "interventions": [ { "name": "Enzelkitug", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2022-10-20", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 10, "location_summary": "San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05581004" }, { "nct_id": "NCT00833833", "title": "MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 259, "start_date": "2008-06", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2016-04-27", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833833" }, { "nct_id": "NCT02248805", "title": "Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Carcinoma" ], "interventions": [ { "name": "MGD007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2014-10", "completion_date": "2018-07-02", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 8, "location_summary": "New Haven, Connecticut • Tampa, Florida • Baltimore, Maryland + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02248805" }, { "nct_id": "NCT05176626", "title": "Long-term Effectiveness of the Antiobesity Medication Phentermine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity", "Obesity; Drug", "Lifestyle, Healthy" ], "interventions": [ { "name": "Online Lifestyle Behavioral Therapy", "type": "BEHAVIORAL" }, { "name": "Phentermine Hydrochloride 8 MG", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 870, "start_date": "2022-06-30", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 4, "location_summary": "Los Angeles, California • Saint Louis Park, Minnesota • Winston-Salem, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Saint Louis Park", "state": "Minnesota" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Bellaire", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176626" }, { "nct_id": "NCT03250676", "title": "Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Estrogen-receptor Positive Breast Cancer", "Cancer, Breast", "Breast Cancer Female", "Breast Adenocarcinoma", "Estrogen Receptor Positive Tumor", "ER Positive" ], "interventions": [ { "name": "H3B-6545", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 151, "start_date": "2017-08-23", "completion_date": "2023-10-26", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 23, "location_summary": "Goodyear, Arizona • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250676" }, { "nct_id": "NCT00735085", "title": "A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "SLV334", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott Products", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 57, "start_date": "2009-04", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2011-09-21", "last_synced_at": "2026-11-15T09:19:05.219Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Dayton, Ohio • Portland, Oregon + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Dayton", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00735085" } ] }